 (1) (1).png){kind=logo}
- 06 Sep 2024, 15:22
#6086
PVPI.jpeg (89.31 KiB) Viewed 1457 times
The Pharmacy Council of India (PCI) has announced the celebration of the 4th National Pharmacovigilance Week from September 17-23, 2024. This important event aims to raise awareness about patient safety and promote a culture of reporting adverse drug reactions (ADRs).
Key Details:
The PCI has requested all pharmacy institutions across India to actively participate in this week-long observance. Institutions are encouraged to prepare and distribute informational and educational materials such as posters, banners, and pamphlets to spread awareness about ADR reporting among the general public.
This initiative aligns with global efforts to improve medication safety and highlights the crucial role pharmacists play in monitoring and reporting adverse drug reactions. By fostering a culture of vigilance and reporting, the pharmacy community can significantly contribute to enhancing patient safety and improving healthcare outcomes.
The announcement comes from the PCI's Registrar-cum-Secretary, Anil Mittal, and has been approved by the competent authority. It demonstrates India's commitment to pharmacovigilance and the continuous improvement of pharmaceutical care.
Reference
Key Details:
- Theme: "Building ADR Reporting Culture for Patient Safety"
- Dates: September 17-23, 2024
- Participants: All pharmacy institutions approved by PCI
The PCI has requested all pharmacy institutions across India to actively participate in this week-long observance. Institutions are encouraged to prepare and distribute informational and educational materials such as posters, banners, and pamphlets to spread awareness about ADR reporting among the general public.
This initiative aligns with global efforts to improve medication safety and highlights the crucial role pharmacists play in monitoring and reporting adverse drug reactions. By fostering a culture of vigilance and reporting, the pharmacy community can significantly contribute to enhancing patient safety and improving healthcare outcomes.
The announcement comes from the PCI's Registrar-cum-Secretary, Anil Mittal, and has been approved by the competent authority. It demonstrates India's commitment to pharmacovigilance and the continuous improvement of pharmaceutical care.
Reference
Attachments:
